Patent ID: 6020379
Filing Date: 2000-02-01
Classification: A61K,C07C

Abstract:
A method of treating a patient having neoplasia comprising administering a pharmacologically effective amount of a compound of Formula I to the patient with a neoplasia sensitive to such a compound: ##STR17## wherein R.sub.1 and R.sub.2 are independently selected in each instance from the group consisting of hydrogen, alkyl, amino, and --C.dbd.O;R.sub.3 is selected from the group consisting of hydrogen and lower alkyl;M is selected from the group consisting of hydroxy, OMe, or NR' R"";Me is a cation;R' is selected from the group consisting of hydrogen, loweralkyl, dialkylaminoalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkenyl, alkynyl, polyhydroxyalkyl, benzyl, phenyl, indane, phenylalkyl, benzylalkyl, pyridinylalkyl, pyrrolylalkyl, pyrrolidinylalkyl, pyrazolylalkyl, pyrazolidinylalkyl, imidazolylalkyl, imidazolidinylalkyl, piperidinylalkyl, pyrazinylalkyl, piperazinylalkyl, pyrimidinylalkyl, morpholinylalkyl, tetrazolylalkyl, triazinylalkyl, furfurylalkyl, thiophenylalkyl, pyridinyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolidinyl, piperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, morpholinyl, tetrazolyl, triazinyl, furfuryl and thiophenyl;R"" is selected from the group consisting of hydrogen, lower alkyl, cyanoalkyl, haloalkyl, aminoalkyl, dialkylamino alkyl, alkanoylalkylester and pyridinylX is selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, S(O).sub.m, --C.dbd.O, --C(O)O--, --O(O)C--, --S(O).sub.2 NR--, --NRS(O).sub.2 --, --C(O)NR--, --NRC(O)--, --CH.sub.2 O, OCH.sub.2 --, --O--, --NR--, --S(O).sub.2 O--, and --OS(O).sub.2 --;R is selected from the group consisting of hydrogen, lower alkyl, and lower alkanoyl;n is 0 or 1; m is 0,1, or 2;R.sub.4, R.sub.5, and R.sub.6 are independently selected in each instance from the group consisting of hydrogen, halogen, alkyl, alkanoyloxy, alkoxy, acylamino, alkylamino, dialkylamino, dialkylaminoalkyl, sulfamyl, alkylthio, hydroxy, hydroxyalkyl, alkenyl, alkenyloxy, alkylsulfonyl, alkylsulfinyl, carboxyl, carbalkoxy, carbamido, and cyano;R.sub.7 is selected from the group consisting of substituted or unsubstituted phenyl, benzyl, pyridinyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolidinyl, piperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, tetrazolyl, morpholinyl, triazinyl, furfryl, and thiophenyl, wherein the substitutents on the R.sub.7 ring are one to three substituents selected from the group consisting of halogen, lower alkyl, lower alkoxy, amino, lower alkylamino, hydroxy, nitro, cyano, dilower alkylamino, lower alkyl mercapto, lower alkyl sulfinyl, lower alkyl sulfonyl, acylamino, hydroxyalkyl, carboxyl, carbalkoxy, and carbamido; and pharmaceutically acceptable salts thereof.